ANKASCIN® 568-R Slide Show
SunWay 2020 annual revenue was 314 million and will be listed on Taiwan Emerging Stock Market on January 18, 2021.
On January 12, SunWay Biotech Co., LTD. (1271) was invited by Fubon Securities Co., Ltd. to participate in the institutional investor conference. John Pan, President of SunWay Biotech, introduced two main ingredients-ANKASCIN 568-R and Vigiis 101-LAB probiotics and their application, and announced that SunWay Biotech will be listed on Taiwan Emerging Stock Market on January 18, 2021.
Dr. Tzu-Ming Pan, head of technology of SunWay Biotech, was invited as speaker in 4th World Congress and Expo on Traditional and Alternative Medicine.
During 14-16 March 2021, 4th World Congress and Expo on Traditional and Alternative Medicine is organized in collaboration with Taipei Chinese Medical Association, Meridian World Health Organization Alliance (MWHOA), Chang Gung University, Tzu Chi University, I Shou University, and China Medical University. The Congress focused on the theme “World Health for everyone with local Wisdom and Resources,” with the domestic well-known speakers and international scholars were invited to publish the research of traditional and alternative medical therapies for global health issues through this online conference. The Head of Technology of SunWay Biotech, Dr. Tzu-Ming Pan, was invited as a speaker by Taipei Chinese Medical Association and Global Scientific Guild to announce at the conference that heart health supplement plays an important role for global health. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally. WHO says that about 17.9 million people worldwide died from CVDs in 2016 alone, representing 31 percent of all global deaths. Moreover, amid the COVID-19 crisis, the global market for Heart Healthy Ingredients estimated at US$16.6 Billion in the year 2020, is projected to reach a revised size of US$24.8 Billion by 2027, growing at a of 5.9% over the analysis period 2020-2027. Red yeast rice, as a dietary supplement ingredient for heart health, is prized for its ability to lower cholesterol […]
With more than ten years of time-consuming and laborious efforts in manifesting the functions and safety, we proudly announce that our NEW red yeast rice extract (ANKASCIN 568-R) has been approved by the US FDA as an NEW DIETARY INGREDIENT (NDI, report # 855).